Publication Name	World Journal of Gastroenterology
Manuscript ID	25972
Country	Japan

Received	2016-03-27 08:48
Peer-Review Started	2016-03-27 14:08
To Make the First Decision	2016-05-12 14:31
Return for Revision	2016-05-13 08:59
Revised	2016-06-30 22:13
Second Decision	2016-07-18 08:59
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2016-08-01 15:25
Articles in Press	2016-08-01 15:25
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-08-17 14:41
Publish the Manuscript Online	2016-09-04 14:49

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma
Manuscript Source	Invited Manuscript
All Author List	Shiro Kimbara and Shunsuke Kondo
Funding Agency and Grant Number	Funding Agency Grant Number JSPS Grant-in-Aid for Young Scientists (B) 268605371 AstraZeneca, Eli Lilly and Company, and Bayer AG
Corresponding Author	Shunsuke Kondo, MD, PhD, Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. shkondo@ncc.go.jp
Key Words	Immune checkpoint; Therapeutic anticancer target; Inflammation; Randomized clinical trial; Pancreatic adenocarcinoma
Core Tip	Pancreatic adenocarcinoma is recognized as one of the most malignant neoplasms, and more efficacious treatment is desired earnestly. Recent research studies have revealed that the development and progression of pancreatic adenocarcinoma are highly influenced by immune responses, and inflammation is a critical promoter of the disease. In this article, we highlighted the emergence of immunosuppression-related signaling associated with immune checkpoint and inflammation, as a novel treatment target for cancer. Furthermore, the review demonstrated that the current focus on therapeutic strategies involving combination chemotherapy, immunotherapy, and anti-inflammation therapy might provide considerably more clinical benefits to patients than current therapies.
Publish Date	2016-09-04 14:49
Citation	Kimbara S, Kondo S. Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. World J Gastroenterol 2016; 22(33): 7440-7452
URL	http://www.wjgnet.com/1007-9327/full/v22/i33/7440.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i33.7440

Full Article (PDF)	WJG-22-7440.pdf
Full Article (Word)	WJG-22-7440.doc
Manuscript File	25972-Review.docx
Answering Reviewers	25972-Answering reviewers.pdf
Audio Core Tip	25972-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	25972-Conflict-of-interest statement.pdf
Copyright License Agreement	25972-Copyright assignment.pdf
Peer-review Report	25972-Peer-review(s).pdf
Scientific Misconduct Check	25972-Scientific misconduct check.pdf
Scientific Editor Work List	25972-Scientific editor work list.pdf